These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25749867)

  • 1. Clinical pharmacokinetics of the anti-interleukin-20 monoclonal antibody NNC0109-0012 in healthy volunteers and patients with psoriasis or rheumatoid arthritis.
    Lundblad MS; Overgaard RV; Göthberg M; Fjording MS; Watson E
    Adv Ther; 2015 Mar; 32(3):228-38. PubMed ID: 25749867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-In-Human, Phase 1, Randomized, Dose-Escalation Trial with Recombinant Anti-IL-20 Monoclonal Antibody in Patients with Psoriasis.
    Gottlieb AB; Krueger JG; Sandberg Lundblad M; Göthberg M; Skolnick BE
    PLoS One; 2015; 10(8):e0134703. PubMed ID: 26252485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Anti-Interleukin-20 Monoclonal Antibody in Patients With Rheumatoid Arthritis: A Randomized Phase IIa Trial.
    Šenolt L; Leszczynski P; Dokoupilová E; Göthberg M; Valencia X; Hansen BB; Cañete JD
    Arthritis Rheumatol; 2015 Jun; 67(6):1438-48. PubMed ID: 25707477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetic evaluation of a fully human IgG monoclonal antibody in patients with inflammatory diseases.
    Tabrizi M; Wang B; Lu H; Huang S; Bell G; Schwab G; Roskos L
    Inflamm Allergy Drug Targets; 2010 Sep; 9(4):229-37. PubMed ID: 20860546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, Safety, and Tolerability of the Dual Inhibitor of Tumor Necrosis Factor-α and Interleukin 17A, ABBV-257, in Healthy Volunteers and Patients With Rheumatoid Arthritis.
    Othman AA; Khatri A; Loebbert R; Peloso PM
    Clin Pharmacol Drug Dev; 2019 May; 8(4):492-502. PubMed ID: 30156758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.
    Zhou H; Jang H; Fleischmann RM; Bouman-Thio E; Xu Z; Marini JC; Pendley C; Jiao Q; Shankar G; Marciniak SJ; Cohen SB; Rahman MU; Baker D; Mascelli MA; Davis HM; Everitt DE
    J Clin Pharmacol; 2007 Mar; 47(3):383-96. PubMed ID: 17322150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis.
    Zhuang Y; Calderon C; Marciniak SJ; Bouman-Thio E; Szapary P; Yang TY; Schantz A; Davis HM; Zhou H; Xu Z
    Eur J Clin Pharmacol; 2016 Nov; 72(11):1303-1310. PubMed ID: 27515978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Confirmatory Population Pharmacokinetic Analysis for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin-6, in Patients With Moderately to Severely Active Rheumatoid Arthritis.
    Xu Y; Hu C; Zhuang Y; Hsu B; Xu Z; Zhou H
    J Clin Pharmacol; 2018 Jul; 58(7):939-951. PubMed ID: 29578578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis.
    Jauslin P; Kulkarni P; Li H; Vatakuti S; Hussain A; Wenning L; Kerbusch T
    Clin Pharmacokinet; 2019 Aug; 58(8):1059-1068. PubMed ID: 30915660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis.
    Bruin G; Loesche C; Nyirady J; Sander O
    J Clin Pharmacol; 2017 Jul; 57(7):876-885. PubMed ID: 28273356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.
    Gaudinski MR; Coates EE; Houser KV; Chen GL; Yamshchikov G; Saunders JG; Holman LA; Gordon I; Plummer S; Hendel CS; Conan-Cibotti M; Lorenzo MG; Sitar S; Carlton K; Laurencot C; Bailer RT; Narpala S; McDermott AB; Namboodiri AM; Pandey JP; Schwartz RM; Hu Z; Koup RA; Capparelli E; Graham BS; Mascola JR; Ledgerwood JE;
    PLoS Med; 2018 Jan; 15(1):e1002493. PubMed ID: 29364886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis.
    Frey N; Grange S; Woodworth T
    J Clin Pharmacol; 2010 Jul; 50(7):754-66. PubMed ID: 20097931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials.
    Suleiman AA; Khatri A; Minocha M; Othman AA
    Clin Pharmacokinet; 2019 Mar; 58(3):375-387. PubMed ID: 30123942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL-23, in Patients with Moderate to Severe Plaque Psoriasis.
    Yao Z; Hu C; Zhu Y; Xu Z; Randazzo B; Wasfi Y; Chen Y; Sharma A; Zhou H
    J Clin Pharmacol; 2018 May; 58(5):613-627. PubMed ID: 29341192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetics of the TNF-α and IL-17A Dual-Variable Domain Antibody ABT-122 in Healthy Volunteers and Subjects With Psoriatic or Rheumatoid Arthritis: Analysis of Phase 1 and 2 Clinical Trials.
    Khatri A; Othman AA
    J Clin Pharmacol; 2018 Jun; 58(6):803-813. PubMed ID: 29364523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis.
    Khatri A; Eckert D; Oberoi R; Suleiman A; Pang Y; Cheng L; Othman AA
    J Clin Pharmacol; 2019 Dec; 59(12):1656-1668. PubMed ID: 31257614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.
    Xu Z; Bouman-Thio E; Comisar C; Frederick B; Van Hartingsveldt B; Marini JC; Davis HM; Zhou H
    Br J Clin Pharmacol; 2011 Aug; 72(2):270-81. PubMed ID: 21392075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetics (PK) and Pharmacodynamics (PD) Analysis of LY3015014, a Monoclonal Antibody to Protein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Healthy Subjects and Hypercholesterolemia Patients.
    Shen T; James DE; Krueger KA
    Pharm Res; 2017 Jan; 34(1):185-192. PubMed ID: 27822850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics analysis of guselkumab in healthy subjects and patients with psoriatic arthritis, plaque psoriasis and palmoplantar pustulosis.
    Tran L; Yao Z; Xu Z; Vermeulen A
    Br J Clin Pharmacol; 2022 Oct; 88(10):4481-4493. PubMed ID: 35470450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studies.
    Endres CJ; Salinger DH; Köck K; Gastonguay MR; Martin DA; Klekotka P; Nirula A; Gibbs MA
    J Clin Pharmacol; 2014 Nov; 54(11):1230-8. PubMed ID: 24846347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.